Kantum Pharma
The business, the turning points, and the decisions behind them.
Some sections are still being researched2 / 4
Sections to complete：02 · 05
01 / WHAT IT BUILT
What the company did
Kantum Pharma was a privately held biopharmaceutical company founded in 2016 in New Hampshire, based on the pioneering work of scientific founder Dr. Sylvie Breton's laboratory at Massachusetts General Hospital/Harvard Medical School. It developed therapies to prevent or reduce inflammation initiated through the UDP-glucose/P2Y14 purinergic receptor signaling pathway in organs such as the kidneys, lungs and female reproductive tract. Its lead small-molecule program, KB-1801, was shown preclinically to reduce renal inflammation and was developed for prevention of acute kidney injury, including cardiac surgery-associated AKI. Investors included Broadview Ventures and private individuals; the company raised about $3.5 million.
02 / FAILURE REASONS
Material for this section is being gathered and checked. It will appear here once ready.
03 / EVENT HISTORY
Events in the structured record
- Founded
Kantum Pharma was founded to translate Dr. Sylvie Breton's UDP-glucose/P2Y14 receptor pathway research at MGH/Harvard Medical School into therapies for acute kidney injury and other inflammatory disorders.
- Funding and research progress
The company raised a $3.5 million round in July 2021 and published preclinical research showing its P2Y14 antagonist reduced kidney inflammation, damage and loss of function in acute kidney injury models.
04 / CONTEMPORARY REBUILD ASSESSMENT
Difficulty of rebuilding this project today
Material for this section is being gathered and checked. It will appear here once ready.
Overall assessment: Not completed
05 / CAUSAL CHAIN / AFTERMATH
Material for this section is being gathered and checked. It will appear here once ready.